.png){kind=icon}
返回
Hepatitis C
.png){kind=icon}
PRE
AI
DOI：10.1016/S0140-6736(23)01320-X.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Hepatitis C virus (HCV) is a hepatotropic RNA virus that can cause acute and chronic hepatitis, with progressive liver damage resulting in cirrhosis, decompensated liver disease, and hepatocellular carcinoma. In 2016, WHO called for the elimination of HCV infection as a public health threat by 2030. Despite some progress, an estimated 57 million people were living with HCV infection in 2020, and 300 000 HCV-related deaths occur per year. The development of direct-acting antiviral therapy has revolutionised clinical care and generated impetus for elimination, but simplified and broadened HCV screening, enhanced linkage to care, and higher coverage of treatment and primary prevention strategies are urgently required.
Keyword:
HIV-POSITIVE MEN
HCV GENOTYPE 1
VIRUS-INFECTION
INJECT DRUGS
SINGLE-ARM
OPEN-LABEL
SPONTANEOUS CLEARANCE
GLOBAL PREVALENCE
PHASE 4
SOFOSBUVIR
期刊
IF:
88.5
论文数:
5.4W
被引数:
34.8W
机构
引用论文
Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study丙型肝炎病毒患病率的全球变化以及护理2015年和2020的级联: 一项建模研究
OAAI
OAAI分享收藏Morbidity and mortality in compensated cirrhosis type C: A retrospective follow-up study of 384 patients.png)
GASTROENTEROLOGY
GASTROENTEROLOGYIF25.1
PREAI
分享收藏Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in PrisonsHEPATOLOGYOAAI
HEPATOLOGYIF15.8
OAAI分享收藏Pregnancy outcome of anti-HCV direct-acting antivirals: Real-life data from an Egyptian cohortLIVER INTERNATIONAL
LIVER INTERNATIONALIF5.2
PREAI
分享收藏
查看更多内容